To Accelerate Development of Treatments for Intractable Diseases
ViGenCell, a biotechnology affiliate of Boryung Pharmaceutical that specializes in immune cell therapy technologies, has launched a scientific advisory committee composed of immunological and clinical research experts to accelerate the development of treatments for intractable diseases and strengthen its research and development capabilities.
The advisory committee will give advice on the development of new drug pipelines and the discovery of new candidate materials based on ViGenCell’s platform technologies.
The company’s platform technologies include ViTier, ViMedier, and ViRanger. ViTier is a customized T-cell therapy using antigen-specific cytotoxic T lymphocytes (CTLs). It is an effective and safe tumor killing T-cell therapy platform technology optimized for target antigens and patients. ViMedier is a general-purpose immunity control cell therapy. It uses Vigencell’s unique technique to proliferate and induce myeloid inhibitory cells from CD34 benign stem cells that are derived rom cord blood. ViRanger is a high-functional general-purpose cell-genetic complex therapy platform technology that can accommodate various genes.
The committee will also be in charge of networking with clinical researchers and related agencies to conduct clinical trials of pipelines at home and abroad. It is composed of three experts, one each for ViTier/ViRanger, ViMedier and clinical science.
Professor Esteban Celis of Georgia Agusta Medical School, a world-renowned authority in immunology related to tumors, will advise on the development of new drugs using ViTier and ViRanger. Professor Celis served as a reviewer at the National Institutes of Health (NIH) and a professor at Mayo Clinic in Minnesota.
Suzanne Ostrand Rosenberg, an adjunct professor of pathology and a member of the Huntsman Cancer Institute at the University of Utah, has been invited as an advisor on the development of new drugs using ViMedier. Professor Rosenberg served as a member of the PREVENT Cancer Preclinical Drug Development Program at the National Cancer Institute under the National Institutes of Health (NIH) and as a professor of biology at the University of Baltimore, Maryland, and is a world-renowned scholar of immunology related to bone marrow-derived inhibiting cells.
Finally, advice on clinical trials will be offered by Moon Han-lim, CEO of Connect Clinical Science. Moon served as director of GSK's Asian medical division on anti-cancer drug research and development and as vice president of ADM Korea, and is considered the best expert in clinical trials with various clinical development consulting experience.